EGFR TKI as first-line treatment for patients with advanced EGFR ...
In this review, we summarize the scientific literature and evidence of EGFR TKIs as first-line therapy from the first-generation EGFR TKIs to conceptually proposed fourth-generation EGFR TKI, and also recommend the application of monotherapy and combination therapies of the EGFR-based targeted therapy with other agents such as chemotherapy ...
EGFR-TKIs or EGFR-TKIs combination treatments for untreated …
1 天前 · Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, the best option has yet to be determined. This study compares the efficacy and safety of various first-line EGFR-TKI monotherapies and combination treatments ...
Comprehensive mutational scanning of EGFR reveals TKI ... - Nature
2024年3月28日 · Here, the authors perform deep mutational scanning of EGFR, followed by a high-throughput functional screen and analysis of patient data, to identify variants with differing sensitivities to a ...
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR ...
Since 2014, EGFR tyrosine kinase inhibitors (EGFR-TKIs) have become the standard first-line therapy for NSCLC patients harboring EGFR-activating mutations (3, 4). When treated with first- or second-generation TKIs, the median progression-free survival (PFS) is ~1 year, whereas with the third-generation TKI osimertinib, it is 18.9 months (5–7 ...
Overcoming therapy resistance in EGFR -mutant lung cancer - Nature
2021年4月15日 · Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth...
Advancements in fourth-generation EGFR TKIs in EGFR
2024年11月1日 · Fourth-generation allosteric EGFR-TKIs are orally bioavailable, thiazole amid-based, EGFR-mutant selective agents that hold the promise of targeting EGFR-activating mutations and simultaneously overcoming C797S-mediated resistance, regardless of T790M, through a selective bond to an allosteric site that alters EGFR conformation, hence bypassing ...
Third-generation EGFR and ALK inhibitors: mechanisms of
2022年5月9日 · Numerous EGFR and ALK tyrosine kinase inhibitors (TKIs) with demonstrated efficacy in patients with EGFR -mutant and ALK -rearranged NSCLCs have been developed, culminating in the...
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal …
Abstract. Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available as first-line treatment options in patients with advanced EGFR-mutant non-small cell lung cancer.Eventual resistance develops with multiple mechanisms identifiable both upon repeat biopsy and in plasma ...
Osimertinib with or without Chemotherapy in EGFR-Mutated …
2023年11月8日 · Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits both...
Overall Survival with Osimertinib in Untreated, EGFR-Mutated …
2019年11月21日 · In patients with advanced or metastatic non–small-cell lung cancer (NSCLC) with mutations in the gene encoding epidermal growth factor receptor (EGFR) that are sensitive to tyrosine kinase...